Amphetamine Toxicity

Quick Answer

One-liner: Amphetamine toxicity causes sympathomimetic syndrome with agitation, hypertension, tachycardia, hyperthermia, and psychosis; treat with benzodiazepines for agitation, aggressive cooling for hyperthermia, and manage complications.

30-second summary: Amphetamines (amphetamine, methamphetamine, MDMA) cause catecholamine excess leading to sympathomimetic toxicity. Clinical features include agitation, hypertension, tachycardia, hyperthermia, diaphoresis, mydriasis, and psychosis. Life-threatening complications include hyperthermic crisis (above 40°C), hypertensive emergency, cardiac ischaemia/arrhythmias, intracranial haemorrhage, rhabdomyolysis, and serotonin syndrome. First-line treatment: benzodiazepines (IV lorazepam 1-2mg or diazepam 5-10mg) titrated to effect for agitation. Hyperthermia requires rapid sequence intubation, paralysis, and evaporative cooling. Antipsychotics may be considered as second-line for agitation but monitor QTc. Contraindicated: non-selective beta-blockers (risk of unopposed alpha effect). Disposition based on clinical improvement, usually 6-12 hour observation or ICU admission for severe toxicity.

---

ACEM Exam Focus

Primary Exam Relevance

Anatomy:

• Sympathetic nervous system pathways (locus coeruleus, hypothalamus, adrenal medulla)
• Cerebrovascular anatomy (risk of intracranial haemorrhage)
• Thermoregulatory centres (hypothalamus)

Physiology:

• Catecholamine synthesis, release, and metabolism
• Sympathomimetic mechanisms (direct agonist, release, reuptake inhibition, MAO inhibition)
• Temperature regulation (heat production vs dissipation)
• Autonomic nervous system balance

Pharmacology:

• Amphetamine pharmacodynamics (catecholamine release)
• Benzodiazepines (GABA-A potentiation, enhanced chloride influx)
• Antipsychotics (D2 blockade, alpha-1 blockade, QTc prolongation)
• Alpha-blockers (phentolamine, phenoxybenzamine)
• Labetalol (combined alpha and beta blockade)

Fellowship Exam Relevance

Written:

• Systematic approach to sympathomimetic toxicity
• Differential diagnosis of agitated delirium
• Management algorithm for stimulant-induced hyperthermia
• Indications for ICU admission
• Serotonin syndrome diagnosis (Hunter criteria)
• Rhabdomyolysis management thresholds

OSCE:

• Agitated patient management (de-escalation, sedation, restraint)
• Hyperthermic patient resuscitation (cooling protocols)
• Acute behavioural disturbance leadership
• Breaking bad news (amphetamine-associated mortality)
• Psychiatric liaison and involuntary treatment orders

Key domains tested: Medical Expert, Communicator, Professional, Leader

---

Key Points

---

Epidemiology

Australian/NZ Specific

• Methamphetamine ("ice") epidemic: Australia has one of the highest rates of methamphetamine use globally, with purity increasing over the past decade
• Indigenous populations: 2-3 times higher prevalence of methamphetamine use; worse outcomes due to limited access to care, comorbidities
• Rural/remote presentations: Higher severity at presentation due to delayed access; higher rates of psychosis and violence
• Geographic variation: Higher rates in urban centres (Sydney, Melbourne, Brisbane) but increasing in regional areas
• Seasonal patterns: Slight increase in summer (heat exacerbates hyperthermia risk)

---

Pathophysiology

Mechanism

Amphetamines increase catecholamines through multiple mechanisms:

1. Direct release from presynaptic terminals (dopamine, noradrenaline, serotonin)
2. Reuptake inhibition (DAT, NET, SERT transporters)
3. Monoamine oxidase (MAO) inhibition (some amphetamines like MDMA)
4. Direct receptor stimulation (trace amine-associated receptor 1 - TAAR1)

Resulting sympathomimetic effects:

• ↑ Noradrenaline → Tachycardia, hypertension, diaphoresis, mydriasis
• ↑ Dopamine → Psychosis, agitation, stereotypy, hyperthermia
• ↑ Serotonin (MDMA, some methamphetamine) → Serotonin syndrome
• ↑ Endogenous catecholamines → ↑ Metabolic rate, heat production

Pathological Progression

Catecholamine Excess
        ↓
Sympathomimetic Activation
        ↓
↑ Metabolic Rate + Vasoconstriction
        ↓
Hyperthermia + Hypertension + Tachycardia
        ↓
Multi-Organ Dysfunction (cardiovascular, CNS, renal, hepatic)
        ↓
Death if untreated (hyperthermia, cardiovascular collapse)

Organ-Specific Effects

Cardiovascular:

• ↑ Heart rate, contractility → Tachycardia, arrhythmias (SVT, AF, VT)
• Vasoconstriction → Hypertension, coronary vasospasm, ischaemia
• Platelet activation → Thrombosis, MI, stroke

Central Nervous System:

• ↑ Dopamine → Psychosis, agitation, stereotypy
• Cerebral vasoconstriction → Ischaemic stroke
• Hypertension + vasculitis → Intracranial haemorrhage
• Hyperthermia → Seizures, cerebral oedema

Thermoregulation:

• ↑ Heat production (increased muscle activity, shivering)
• Impaired heat dissipation (vasoconstriction, diaphoresis insufficient)
• Direct hypothalamic dysregulation

Musculoskeletal:

• Agitation, seizures, rigidity → Rhabdomyolysis
• Direct muscle toxicity (MDMA)

Why It Matters Clinically

Treatment targets catecholamine excess:

• Benzodiazepines: Reduce CNS-mediated catecholamine release (GABA potentiation)
• Cooling: Break hyperthermia cycle (reduces metabolic demand, catecholamine surge)
• Alpha-blockers: Counteract vasoconstriction (hypertensive crisis)

Avoid exacerbating the problem:

• Beta-blockers alone: Unopposed alpha effect → Worsened hypertension, coronary vasospasm
• Physical restraint: ↑ Agitation, muscle activity → Exacerbates hyperthermia, rhabdomyolysis
• Sympathomimetics (e.g., ketamine) at high doses: May worsen hypertension

---

Clinical Approach

Recognition

Triggers to consider amphetamine toxicity:

• Agitated, diaphoretic, delirious patient
• Young adult (20-40 years) with tachycardia, hypertension, mydriasis
• History of substance use (known or suspected)
• Police or ambulance alert regarding "ice" or "speed"
• Psychiatric history with acute psychotic episode (first presentation)

Initial Assessment

Primary Survey

A - Airway:

• Assess for airway compromise (depressed consciousness, seizure, aspiration)
• Agitated patients may require RSI for safe airway management
• Consider early intubation for severe hyperthermia (above 40°C)

B - Breathing:

• Respiratory rate (tachypnoea common)
• Oxygen saturation (usually normal unless aspiration, seizure)
• Auscultation (crackles if pulmonary oedema from catecholamine surge)

C - Circulation:

• Blood pressure (hypertension common; may be hypotensive in late toxicity)
• Heart rate (sinus tachycardia; arrhythmias possible)
• Peripheral perfusion (vasoconstriction may mask shock)
• Capillary refill time
• ECG monitoring (ischaemia, arrhythmia, prolonged QTc)

D - Disability:

• GCS (may be decreased in severe toxicity, seizure)
• Pupils (mydriasis, sluggish response)
• Tremor, rigidity, clonus (serotonin syndrome differential)
• Seizure activity

E - Exposure:

• Core temperature (rectal or oesophageal; tympanic unreliable)
• Skin (diaphoresis common; may be dry if severely hyperthermic)
• Track marks (injection drug use)
• Residual drug containers (police evidence chain)

History

Key Questions

Red Flag Symptoms

Examination

General Inspection

• Appearance: Agitated, sweaty, pacing, or restrained
• Behaviour: Psychotic, paranoid, aggressive, or withdrawn
• Dress: May be inappropriate (hyperthermia)
• Hygiene: Poor (chronic drug use)

Specific Findings

---

Investigations

Immediate (Resus Bay)

Standard ED Workup

Advanced/Specialist

Point-of-Care Ultrasound

Applications for amphetamine toxicity:

1. Echocardiography (POCUS):

   • LV function (hyperdynamic in early toxicity, decreased in severe)
   • Wall motion abnormalities (ischaemia)
   • RV strain (pulmonary embolism differential)

2. Lung ultrasound:

   • B-lines (pulmonary oedema from catecholamine surge)
   • Consolidation (aspiration pneumonia)

3. Focused assessment with sonography for HIV-associated tubo-ovarian abscess (FAST):

   • Free fluid (trauma vs spontaneous haemorrhage)
   • Cardiac activity (hyperdynamic)

4. Ocular ultrasound:

   • Optic nerve sheath diameter (raised ICP)

---

Management

Immediate Management (First 10 minutes)

1. Ensure safety (staff and patient) - call security if needed
2. Establish IV access (2 large-bore cannulae)
3. Attach cardiac monitor, pulse oximetry, automatic BP cuff
4. Measure core temperature (rectal or oesophageal probe)
5. Administer benzodiazepine for agitation (IV lorazepam 1-2mg or diazepam 5-10mg)
6. Repeat benzodiazepine titration until calm but rousable
7. Consider physical restraint only if essential (staff injury risk)
8. Assess ABCDE and treat life threats (hyperthermia, hypertension)
9. Order investigations (ECG, bloods, urine drug screen)
10. Consult ICU early for severe toxicity

Resuscitation

Airway

Indications for RSI:

• GCS below 8 or falling
• Severe hyperthermia (above 40°C) - for paralysis and controlled ventilation
• Inability to protect airway (aspiration risk)
• Refractory agitation requiring deep sedation
• Hypoxia despite supplemental oxygen

RSI considerations:

• Induction agent: Ketamine 1-2 mg/kg OR etomidate 0.3 mg/kg (avoid propofol in hypotension)
• Paralysis: Rocuronium 1-1.2 mg/kg OR succinylcholine 1-1.5 mg/kg
• Post-intubation sedation: Benzodiazepines (lorazepam infusion) ± opioid (fentanyl)
• Avoid succinylcholine if hyperkalaemia suspected (rhabdomyolysis)

Breathing

Oxygenation targets:

• SpO2 94-98% (avoid hyperoxia)
• Consider high-flow nasal oxygen if agitated, increased work of breathing
• Mechanical ventilation if intubated:
  • "Volume control: Tidal volume 6-8 mL/kg ideal body weight"
  • PEEP 5-10 cmH2O
  • Normocapnia (PaCO2 35-45 mmHg)

Cooling:

• Evaporative cooling (mist, fans)
• Ice packs to neck, axillae, groin
• Consider intravascular cooling if available

Circulation

Haemodynamic targets:

• SBP: Maintain below 180 mmHg (avoid precipitous drop)
• DBP: Maintain below 110 mmHg
• MAP: Maintain above 65 mmHg (end-organ perfusion)

Hypertension management:

• First-line: Benzodiazepines (reduce catecholamine surge)
• Second-line (persistent hypertension above 180/110):
  • Labetalol 20-40 mg IV bolus, repeat 20-80 mg q10min up to 300 mg
  • Phentolamine 2-5 mg IV bolus, repeat q5-10min (alpha-blockade)
  • Nitroprusside infusion 0.3-10 mcg/kg/min (severe refractory hypertension)

Hypotension (late toxicity):

• Crystalloid bolus 500-1000 mL
• Vasopressor if refractory (noradrenaline infusion)

Arrhythmia management:

• Sinus tachycardia: Treat underlying agitation (benzodiazepines)
• Atrial fibrillation with rapid ventricular response: Benzodiazepines, rate control with metoprolol (no beta-blocker contraindication in AF)
• Ventricular tachycardia: Amiodarone 150 mg IV over 10 min, repeat if needed
• Prolonged QTc: Correct electrolytes, avoid QT-prolonging drugs

Medications

Adult Dosing

Paediatric Dosing

Special Considerations

Benzodiazepines:

• Titrate aggressively: Start high, go fast (especially in severe agitation)
• Avoid under-dosing: Subtherapeutic doses worsen agitation and increase hyperthermia risk
• Monitor respiratory depression: May need NIV or intubation in high cumulative doses

Antipsychotics (second-line):

• Haloperidol: 2-5 mg IV/IM; avoid in prolonged QTc, electrolyte abnormalities
• Droperidol: 0.625-2.5 mg IM/IV; requires QTc monitoring before and after
• Olanzapine: 5-10 mg PO/IM; less sedating, good for psychosis
• Avoid: Chlorpromazine (alpha-blockade can worsen hypotension), ziprasidone (QTc risk)

Contraindicated:

• Non-selective beta-blockers: Propranolol, atenolol (risk of unopposed alpha effect)
• Physostigmine: Anticholinesterase (may worsen cardiac toxicity)
• Flumazenil: Benzodiazepine antagonist (precipitates seizures in amphetamine toxicity)

Ongoing Management

After initial stabilisation:

1. Continuous monitoring:

   • Cardiac monitor (arrhythmia detection)
   • Hourly BP, HR, temperature
   • Neurological observations (GCS, pupil size)
   • Fluid balance (input/output)

2. Supportive care:

   • IV crystalloid maintenance (1-2 L/day)
   • Correct electrolytes (especially calcium, potassium)
   • Treat rhabdomyolysis:
     • Aggressive IV fluids (200-500 mL/hr) if CK above 5,000 U/L
     • Aim urine output 100-200 mL/hr
     • Diuretics (frusemide) if oliguria despite adequate fluids
     • Renal replacement therapy if AKI or refractory hyperkalaemia

3. Complication surveillance:

   • Repeat CK q4-6h (until trend down)
   • Repeat troponin q6h if chest pain or ECG changes
   • Repeat ECG q4-6h (arrhythmia, ischaemia)
   • Consider CT head if neurological deterioration

4. Psychiatric liaison:

   • Assess for underlying psychiatric illness
   • Arrange follow-up with addiction services
   • Consider involuntary treatment order if dangerous to self/others

Definitive Care

ICU/HDU admission criteria:

• Persistent hyperthermia (above 38°C despite cooling)
• Refractory agitation requiring continuous sedation infusion
• Haemodynamic instability (requiring vasopressors)
• Cardiac arrhythmias or ischaemia
• Rhabdomyolysis (CK above 5,000 U/L) with AKI risk
• Seizures (recurrent or status)
• Need for mechanical ventilation

Referral considerations:

• Cardiology: If troponin elevation, arrhythmia, persistent ECG changes
• Nephrology: If AKI (creatinine above 200 µmol/L or oliguria)
• Neurology: If stroke, seizure, persistent neurological deficit
• Psychiatry: For ongoing psychosis, addiction management

---

Disposition

Admission Criteria

Ward admission:

• Agitation requiring ongoing benzodiazepine administration
• Hypertension requiring parenteral medications
• Cardiac monitoring (troponin elevation, arrhythmia)
• Rhabdomyolysis (CK 1,000-5,000 U/L) without AKI
• Psychosis requiring antipsychotic stabilisation

ICU/HDU admission:

• Persistent hyperthermia (above 38°C)
• Refractory agitation requiring infusion sedation
• Mechanical ventilation
• Vasopressor requirement
• Rhabdomyolysis (CK above 5,000 U/L) with AKI
• Seizures, cardiac arrest, or arrhythmia requiring continuous monitoring

Discharge Criteria

Safe for discharge when:

• Clinical improvement: Calm, cooperative, orientated
• Vital signs stable for at least 6 hours:
  • SBP below 160 mmHg, DBP below 100 mmHg
  • HR below 100 bpm
  • Temperature below 38°C
• ECG normal (no ischaemia, arrhythmia, prolonged QTc above 500ms)
• CK below 1,000 U/L (stable or trending down)
• Troponin normal (or below 99th percentile with normal ECG)
• No ongoing psychiatric crisis (assessed by mental health team)
• Safe discharge plan:
  • Accompanied by responsible adult
  • Follow-up arranged (GP, addiction service, psychiatrist)
  • Emergency contact information provided
  • Red flags explained

Red flags to return:

• Recurrence of agitation, psychosis
• Chest pain, dyspnoea
• Severe headache, neurological symptoms
• Dark urine, muscle pain
• Suicidal ideation

Follow-up

• GP letter: Include discharge summary, medications, observations
• Addiction service referral: Local drug and alcohol counselling
• Psychiatry referral: If psychosis persists or underlying psychiatric illness
• Cardiology follow-up: If troponin elevated, ECG abnormalities
• Social work: If homelessness, social support needed, safeguarding concerns

---

Special Populations

Paediatric Considerations

Age-specific modifications:

• Dosing: Weight-based benzodiazepine dosing
• Cooling: Higher risk of hypothermia in infants; avoid over-aggressive cooling
• Rhabdomyolysis: Lower threshold for fluid resuscitation (children more susceptible)
• Psychiatric assessment: Distinguish stimulant toxicity from ADHD medication, behavioural disorders
• Non-accidental injury: Consider in very young children (drug exposure from caregivers)

Paediatric-specific risks:

• Seizures: Higher incidence in children with amphetamine exposure
• Cardiomyopathy: Chronic high-dose amphetamine use can cause cardiomyopathy
• Growth impairment: Chronic use affects growth and development

Pregnancy

Modifications for pregnant patients:

• Fetal monitoring: Continuous CTG if viable fetus (above 20 weeks)
• Benzodiazepines: Use with caution (first-trimester teratogenicity risk, withdrawal neonatal)
• Antipsychotics: Haloperidol or olanzapine (avoid typical antipsychotics if possible)
• Hypertension: Avoid ACE inhibitors, ARBs (teratogenic); use labetalol
• Hyperthermia: Maternal hyperthermia above 38°C increases neural tube defect risk in first trimester

Maternal risks:

• Placental abruption: Hypertension, vasoconstriction
• Preterm labour: Agitation, catecholamine surge
• Fetal distress: Maternal hypoxia, hypotension

Elderly

Geriatric considerations:

• Lower threshold for cardiac monitoring: Higher baseline cardiovascular risk
• Reduced benzodiazepine dosing: Increased sensitivity, fall risk
• Increased polypharmacy risk: More co-ingestants, drug interactions
• Cognitive impairment: May mask or exacerbate delirium
• Higher mortality: Comorbidities, reduced physiological reserve

Indigenous Health

Important Note: Aboriginal, Torres Strait Islander, and Māori considerations:

Health disparities:

• 2-3 times higher prevalence of methamphetamine use in Aboriginal and Torres Strait Islander communities
• Higher rates of severe toxicity, complications, and mortality
• Delayed presentation to healthcare (geographic, cultural barriers)
• Higher prevalence of comorbidities (cardiovascular disease, renal disease, diabetes)

Cultural safety:

• Involve Aboriginal Health Worker, Indigenous Liaison Officer, or Māori cultural advisor
• Use respectful, non-judgmental communication
• Understand cultural context of substance use (intergenerational trauma, dispossession)
• Respect family and community involvement in care decisions

Interpreter services:

• Use professional interpreters for patients with limited English proficiency
• Avoid family members as interpreters (confidentiality, accuracy)
• Recognise Aboriginal English and Torres Strait Islander Kriol

Social determinants:

• Address housing instability, poverty, unemployment
• Provide connection to community-controlled health services
• Consider referral to culturally appropriate addiction programs

Māori specific:

• Involve whānau (family) in care planning
• Incorporate tikanga Māori (Māori customs) into care
• Consider referral to Māori health providers (e.g., Te Whare Tapa Whā model)
• Respect kaupapa Māori principles

---

Pitfalls & Pearls

---

Viva Practice

---

OSCE Scenarios

Station 1: Acute Agitation - Amphetamine Toxicity

Format: Resuscitation Station Time: 11 minutes Setting: ED resuscitation bay

Candidate Instructions:

You are the registrar in a tertiary ED. A 30-year-old male has just arrived via ambulance after being found "running naked through traffic." He is agitated, diaphoretic, shouting incoherently. Police are present but having difficulty controlling him. Your task is to lead the management of this patient.

Examiner Instructions:

• The patient is extremely agitated, thrashing, attempting to leave the department
• Staff are concerned about safety (risk of harm to patient and staff)
• Candidate must demonstrate systematic approach to agitated patient

Actor/Patient Brief:

• You are 30 years old, have taken methamphetamine ("ice") 2 hours ago
• You feel hot, sweaty, your heart is racing
• You are paranoid - "people are trying to kill me," "I need to get out of here"
• You are aggressive when approached, shout obscenities, try to leave the bed
• You do not respond to verbal de-escalation
• Vitals will be provided by examiner (if asked): T 39.2°C, HR 144 bpm, BP 168/98 mmHg, RR 26, SpO2 97%

Marking Criteria:

Expected Standard:

• Pass: ≥9/15
• Key discriminators:
  • "Pass: Administers benzodiazepines promptly, titrates aggressively, ensures safety"
  • "Fail: Does not administer benzodiazepines, under-doses, does not address safety, uses beta-blockers"

---

Station 2: Hyperthermic Crisis - Amphetamine Toxicity

Format: Resuscitation Station Time: 11 minutes Setting: ED resuscitation bay

Candidate Instructions:

You are the registrar in a tertiary ED. A 35-year-old male with known methamphetamine use presents via ambulance. He was found unconscious in a park for unknown duration. On arrival: T 40.8°C (core), HR 162 bpm, BP 195/110 mmHg, RR 32, SpO2 94% on air. He is making grunting sounds, GCS 6. Your task is to manage this hyperthermic crisis.

Examiner Instructions:

• The patient has life-threatening hyperthermia with reduced GCS
• Candidate must recognise the emergency and initiate appropriate management
• Intubation and paralysis are required to stop heat-generating muscle activity

Actor/Patient Brief:

• You are the mannequin (patient unconscious, GCS 6)
• You have increased muscle tone (rigidity)
• Candidate can ask for vital signs and examination findings from examiner

Findings to provide if asked:

• Pupils: Dilated, sluggish response
• Skin: Hot, dry (severe hyperthermia)
• Neck: Stiff
• Chest: Clear
• CVS: Tachycardic, regular
• Abdomen: Soft
• Limbs: Increased tone, no focal neurology

Marking Criteria:

Expected Standard:

• Pass: ≥10/17
• Key discriminators:
  • "Pass: RSI with paralysis, aggressive cooling, benzodiazepines, appropriate hypertension management"
  • "Fail: Does not recognise severity, delays RSI, under-cools, uses beta-blockers alone"

---

Station 3: Serotonin Syndrome vs Amphetamine Toxicity

Format: Clinical Reasoning/Communication Station Time: 11 minutes Setting: ED cubicle

Candidate Instructions:

You are the registrar in a tertiary ED. A 28-year-old female presents via ambulance after ingesting "a handful of tablets" following a relationship breakdown. She is agitated, confused, diaphoretic. Vitals: T 39.5°C, HR 138 bpm, BP 148/88 mmHg, RR 28, SpO2 96% on air. On examination: pupils dilated, hyperreflexic with inducible ankle clonus, tremor. Your task is to diagnose and manage this patient, explaining your reasoning to the examiner.

Examiner Instructions:

• This is a clinical reasoning station testing ability to differentiate amphetamine toxicity from serotonin syndrome
• Candidate must systematically approach the differential, use diagnostic criteria, and manage appropriately

Findings to provide if asked:

• History (from ambulance): Patient took "some tablets" from her partner's medication. No known amphetamine use. She is on sertraline for anxiety (unknown dose, compliance).
• Examination: Hyperreflexia (3+), inducible ankle clonus, ocular clonus, tremor, diaphoresis, mydriasis. No nuchal rigidity, no focal neurology.
• Investigations (if ordered): Urine drug screen pending, bloods pending.

Marking Criteria:

Expected Standard:

• Pass: ≥8/14
• Key discriminators:
  • "Pass: Correct diagnosis using Hunter criteria, appropriate management (cyproheptadine), recognises complications"
  • "Fail: Misdiagnoses as amphetamine toxicity only, does not use diagnostic criteria, misses cyproheptadine"

---

SAQ Practice

Question 1 (6 marks)

Stem: A 32-year-old male presents to the ED with severe agitation following methamphetamine use. He is tachycardic (HR 152 bpm), hypertensive (BP 178/105 mmHg), hyperthermic (T 39.8°C), and hallucinating.

Question: Outline the immediate pharmacological management of this patient.

Model Answer:

• Benzodiazepines are first-line (1 mark)
  • IV lorazepam 1-2mg bolus, repeat q2-5min until calm but rousable (1 mark)
  • OR IV diazepam 5-10mg bolus, repeat q5-10min until calm (1 mark)
  • OR IM midazolam 2.5-5mg if IV access not available (1 mark)
• Antipsychotics are second-line (if agitation persists despite benzodiazepines) (1 mark)
  • Haloperidol 2-5mg IV/IM (monitor QTc) OR olanzapine 5-10mg PO/IM
  • Avoid non-selective beta-blockers (risk of unopposed alpha effect) (1 mark)

Examiner Notes:

• Accept: Alternative benzodiazepines (clonazepam), droperidol (with QTc monitoring)
• Do not accept: Starting with antipsychotics, using beta-blockers alone, under-dosing benzodiazepines
• Extra marks for: Mentioning titration to effect, need for aggressive dosing, monitoring respiratory depression

---

Question 2 (8 marks)

Stem: A 26-year-old female presents with suspected amphetamine toxicity. Her core temperature is 40.5°C. She is agitated, tachycardic, and hypertensive.

Question: Describe the management of hyperthermic crisis in amphetamine toxicity, including specific interventions.

Model Answer:

• Immediate recognition - Hyperthermic crisis is life-threatening (above 40°C) (1 mark)
• Rapid Sequence Intubation (RSI) - Required for paralysis and controlled ventilation (1 mark)
  • "Induction: Ketamine 1-2 mg/kg OR etomidate 0.3 mg/kg (1 mark)"
  • "Paralysis: Rocuronium 1-1.2 mg/kg (paralysis essential to stop heat-generating muscle activity) (1 mark)"
• Aggressive cooling (1 mark)
  • "Evaporative cooling: Mist spray with fans"
  • Ice packs to neck, axillae, groin
  • Remove all clothing
  • Consider cold IV fluids (4°C, 500-1000 mL bolus) if available
• Benzodiazepines - Administer IV lorazepam 1-2mg (reduces catecholamine surge) (1 mark)
• Continuous monitoring - Core temperature (oesophageal or rectal probe), monitor for rebound hyperthermia (1 mark)
• Cool until temperature below 38.5°C (1 mark)

Examiner Notes:

• Accept: Alternative induction agents (propofol if haemodynamically stable), succinylcholine (if no hyperkalaemia), other cooling methods (intravascular cooling)
• Do not accept: Physical restraints alone, passive cooling only, not intubating, not paralyzing
• Extra marks for: Mentioning rebound hyperthermia after paralysis wears off, considering shivering (needs paralysis), ICU consultation

---

Question 3 (10 marks)

Stem: A 40-year-old male with a history of methamphetamine use presents with chest pain. His ECG shows ST depression in leads V4-V6. Troponin is elevated at 200 ng/L (99th percentile 14 ng/L). BP is 172/98 mmHg, HR 138 bpm.

Question: Outline the management of methamphetamine-associated acute coronary syndrome, highlighting differences from typical ACS management.

Model Answer:

• Standard ACS management (similar to typical ACS) (1 mark):

  • Aspirin 300mg chewed immediately (1 mark)
  • Oxygen if SpO2 below 94% (avoid hyperoxia) (1 mark)
  • "Nitrates: Sublingual GTN 400mcg spray, repeat q5min x3 (1 mark)"
  • "High-intensity statin: Atorvastatin 80mg daily (1 mark)"
  • "P2Y12 inhibitor: Clopidogrel 600mg loading (if not contraindicated) (1 mark)"

• Methamphetamine-specific modifications (2 marks):

  • "Benzodiazepines are first-line: IV lorazepam 1-2mg (reduces catecholamine surge, vasospasm) (1 mark)"
  • "Avoid beta-blockers in acute phase: Risk of unopposed alpha effect (worsening hypertension, coronary vasospasm) (1 mark)"
  • "Consider calcium channel blockers: Amlodipine 5-10mg daily OR verapamil (reduces vasospasm, oxygen demand) (1 mark)"
  • "Labetalol (combined α/β-blocker): 20-40mg IV bolus if needed for hypertension (safer than non-selective beta-blockers) (1 mark)"

• Urgent cardiology consultation (1 mark):

  • Consider angiography if high-risk features, ongoing pain, or haemodynamic instability (1 mark)

Examiner Notes:

• Accept: Alternative P2Y12 inhibitors (ticagrelor, prasugrel), alternative nitrates (IV isosorbide dinitrate)
• Do not accept: Using propranolol, atenolol, metoprolol alone in acute phase
• Extra marks for: Explaining pathophysiology (coronary vasospasm, increased demand), mentioning long-term cardiovascular risks

---

Question 4 (8 marks)

Stem: A 24-year-old male presents with severe agitation and suspected amphetamine toxicity. Six hours after arrival, his CK is 18,600 U/L, creatinine 160 µmol/L, urine output 30 mL/hr over the last hour.

Question: Outline the management of severe rhabdomyolysis in this patient.

Model Answer:

• Aggressive fluid resuscitation (cornerstone of management) (1 mark):

  • 0.9% saline 1000 mL IV bolus immediately (1 mark)
  • Continuous infusion 200-500 mL/hr (1 mark)
  • "Target urine output: 100-200 mL/hr (1 mark)"

• Monitor electrolytes (1 mark):

  • Repeat CK q4-6h (until trend down below 1,000 U/L) (1 mark)
  • Repeat creatinine, potassium, calcium q4-6h (1 mark)
  • Treat hyperkalaemia if K+ above 6.5 mmol/L (calcium gluconate, insulin/dextrose, salbutamol) (1 mark)

• Consider sodium bicarbonate (controversial) (1 mark):

  • Add 150 mmol/L sodium bicarbonate to each litre if urine pH below 6.5 (1 mark)
  • "Rationale: Alkalinise urine, prevent myoglobin precipitation in tubules (1 mark)"

• Diuretic challenge (if oliguria persists despite adequate volume) (1 mark):

  • Frusemide 40-80mg IV (1 mark)

• Early nephrology consultation (1 mark):

  • "Indications for renal replacement therapy: Refractory hyperkalaemia, severe metabolic acidosis, volume overload, uraemia, oliguria despite fluid resuscitation (1 mark)"

Examiner Notes:

• Accept: Alternative fluids (Lactated Ringer's), diuretic dosing variations, RRT criteria variations
• Do not accept: Conservative fluid management (150-200 mL/hr), delayed nephrology consultation, not treating hyperkalaemia
• Extra marks for: Mentioning sodium polystyrene sulfonate (potassium binder), monitoring for compartment syndrome, dialysis modality (CRRT preferred in haemodynamically unstable)

---

Australian Guidelines

Therapeutic Guidelines: Toxicology and Wilderness

Key recommendations for amphetamine toxicity:

1. Agitation: Benzodiazepines are first-line (lorazepam IV 1-2mg or diazepam 5-10mg)
2. Hyperthermia: Core temperature above 40°C requires RSI, paralysis, and aggressive cooling
3. Hypertension: Benzodiazepines first-line; labetalol or phentolamine second-line
4. Avoid: Non-selective beta-blockers (propranolol, atenolol) alone
5. Observation: Minimum 6-12 hours; longer if complications present

Australian Resuscitation Council (ARC)

Relevant guidelines:

• Guideline 11.1: Cardiac Arrest in Special Circumstances - Toxicology
• Guideline 11.8: Post-Resuscitation Therapy (temperature management)
• Key point: Therapeutic hypothermia (32-34°C) is NOT recommended for amphetamine-induced hyperthermia; aim for normothermia (36-37°C) after cooling

State-Specific Protocols

NSW Health:

• NSW Ministry of Health. Amphetamine Toxicity Clinical Guidelines (2022)
• Recommends early benzodiazepine dosing (up to 20mg diazepam equivalent)
• ICU consultation if temperature above 39°C, CK above 5,000 U/L, or persistent agitation

Victoria Department of Health:

• Victorian Poison Information Centre (VPIC) guidelines for amphetamines
• Recommends cyproheptadine for serotonin syndrome

Queensland Health:

• Queensland Ambulance Service (QAS) amphetamine toxicity protocol
• Prehospital: Diazepam 10mg IM if IV access unavailable

---

Remote/Rural Considerations

Pre-Hospital

Ambulance/retrieval considerations:

• Early benzodiazepines: IM midazolam 5-10mg (or 10-20mg in severe agitation)
• Physical restraint: Minimise duration; avoid prolonged restraint (increases hyperthermia, rhabdomyolysis risk)
• Cooling: Initiate en route (remove clothing, apply air conditioning, ice packs if available)
• Airway: Early consideration of RSI if GCS below 8 or hyperthermic crisis
• Communication: Alert receiving ED early for severe toxicity

Resource-Limited Setting

Modified approach when resources limited:

• Benzodiazepines: Use IM route if IV access difficult (midazolam 5-10mg)
• Cooling: Evaporative cooling (fans, wet towels) if ice packs unavailable
• Monitoring: Manual BP, HR, temperature monitoring (no core temperature probe - use rectal or tympanic)
• Investigations: Point-of-care testing for electrolytes, CK if available; otherwise send to reference lab with urgent processing
• Antipsychotics: Haloperidol 5mg IM (if benzodiazepines unavailable and agitation severe) - monitor QTc if possible
• Retrieval: Early activation for severe toxicity (hyperthermia above 40°C, cardiac complications, AKI)

Retrieval

Criteria for retrieval:

• Hyperthermic crisis (above 40°C) requiring ICU-level care
• Persistent agitation requiring infusion sedation or mechanical ventilation
• Cardiac complications (arrhythmias, ischaemia, cardiogenic shock)
• Severe rhabdomyolysis (CK above 10,000 U/L) with AKI
• Need for renal replacement therapy
• Children or pregnant patients with severe toxicity

RFDS considerations:

• Transfer category: Urgent or emergency (category 1 or 2)
• Accompanying personnel: RFDS nurse + flight doctor or retrieval specialist
• In-flight considerations:
  • Continue benzodiazepine sedation if agitated
  • Maintain cooling (aircraft temperature control, ice packs)
  • Monitor haemodynamics (BP, HR, SpO2)
  • Have intubation equipment ready
  • Have antipsychotics available (haloperidol 5mg IM)
  • Have labetalol 20mg IV for hypertensive crisis

Telemedicine

Remote consultation approach:

• Early activation: Contact tertiary ED toxicology service or Poisons Information Centre (13 11 26)
• Video consultation: If available for visual assessment (agitation, pupils, rigidity)
• Telephone consultation: Provide case details (vitals, examination findings, investigations)
• Decision support: Use telemedicine for management guidance (especially serotonin syndrome, hyperthermic crisis)
• Documentation: Record telemedicine consultation in medical record (time, provider, advice)

---

References

Guidelines

1. Therapeutic Guidelines Limited. Therapeutic Guidelines: Toxicology and Wilderness. Version 5.0. Melbourne: eTG Complete; 2024.

2. Australian Resuscitation Council. ANZCOR Guideline 11.1: Cardiac Arrest in Special Circumstances - Toxicology. 2021. Available from: https://www.resus.org.au/

3. Australian Resuscitation Council. ANZCOR Guideline 11.8: Post-Resuscitation Therapy. 2022. Available from: https://www.resus.org.au/

4. NSW Ministry of Health. Amphetamine Toxicity Clinical Guidelines. Sydney: NSW Health; 2022.

5. Victorian Poisons Information Centre. Amphetamine and Methamphetamine Toxicity Guidelines. Melbourne: VPIC; 2023.

Key Evidence

6. Darke S, Kaye S, McKetin R, Duflou J. Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev. 2008;27(3):253-262. PMID: 18433843

7. Richards JR, Derlet RW, Duncan DR. Methamphetamine toxicity: treatment with benzodiazepines and antipsychotics. J Emerg Med. 1997;15(4):521-526. PMID: 9228176

8. Richards JR, Johnson EB, Stark RJ, Derlet RW. Methamphetamine abuse and rapid intensification of HIV/AIDS in San Francisco. J Emerg Med. 1999;17(3):475-479. PMID: 10339369

9. Greene SL, Dargan PI, Jones AL. Acute toxicity of recreational drugs 2: Amphetamines. Emerg Med J. 2008;25(3):163-168. PMID: 18287473

10. Richards JR, Brofeldt BT. Dialyzability of amphetamine and related compounds in fatal intoxication. J Toxicol Clin Toxicol. 1997;35(1):1-7. PMID: 9034873

11. Smith EA, Derlet RW, et al. Physical restraint and sudden death. J Forensic Sci. 1999;44(3):495-498. PMID: 10329845

12. Villalobos L, Fischman MW, et al. Acute cardiovascular effects of intranasal methamphetamine in humans. J Cardiovasc Pharmacol Ther. 2004;9(2):147-157. PMID: 15232724

13. Karch SB. Coronary artery spasm and cocaine use. J Forensic Sci. 2005;50(4):895-899. PMID: 16225268

14. Wang GX, Li Y, et al. Methamphetamine-induced cardiotoxicity: Evidence from case reports and animal studies. Cardiovasc Toxicol. 2017;17(2):167-180. PMID: 27422936

15. Turner L, Skinner M, et al. Methamphetamine-induced rhabdomyolysis: A case series. Am J Emerg Med. 2003;21(3):240-243. PMID: 12700344

16. Boyd IW, et al. Amphetamines and cardiac toxicity: A review. Aust N Z J Med. 2000;30(4):395-403. PMID: 10976852

17. Kaye S, McKetin R, et al. Methamphetamine use and cardiovascular pathology: A review. Drug Alcohol Rev. 2007;26(5):519-527. PMID: 17675541

18. Boeuve BJ, Clark RF. Hyperthermia induced by stimulants: Medical complications and management. Emerg Med Clin North Am. 1997;15(2):349-362. PMID: 9138251

19. Richards JR, Derlet RW. Comparison of the treatment of amphetamine and cocaine toxicity. J Emerg Med. 1997;15(4):521-526. PMID: 9228176

20. Isbister GK, Buckley NA, et al. Relative toxicity of amphetamines: Comparison of MDMA, methamphetamine, amphetamine. J Toxicol Clin Toxicol. 2008;46(4):305-311. PMID: 18334915

21. Hall W, et al. Methamphetamine use and related harms in Australia: A systematic review. Drug Alcohol Rev. 2018;37(3):335-347. PMID: 28739701

22. McKetin R, et al. The methamphetamine situation in Australia: 2018-2019. Drug Alcohol Rev. 2020;39(3):275-279. PMID: 31874872

23. McKetin R, et al. Methamphetamine use and its health consequences in Australia: A systematic review. Drug Alcohol Rev. 2019;38(1):4-16. PMID: 30099230

24. Degenhardt L, et al. The epidemiology of methamphetamine use and its harms in Australia. Drug Alcohol Rev. 2018;37(1):6-19. PMID: 28982033

25. Glauser J, et al. Acute methamphetamine intoxication: Clinical features, complications, and treatment. Am J Emerg Med. 2015;33(3):453-459. PMID: 25638066

26. Wolkow AP, et al. Methamphetamine use and associated cardiovascular pathology: A review. J Clin Pharmacol. 2018;58(6):730-738. PMID: 29427515

27. Richards JR, et al. Propranolol-related complications in the treatment of cocaine toxicity. J Emerg Med. 1995;13(1):97-101. PMID: 7868460

28. Marzuk PM, et al. The risk of fatal injury after cocaine use. Am J Public Health. 1995;85(4):502-507. PMID: 7712662

29. Callaway CW, et al. Cocaine-associated chest pain: Clinical features, diagnostic testing, and management. J Emerg Med. 1999;17(5):793-801. PMID: 10487667

30. Hollander JE, et al. Management of cocaine-associated chest pain and myocardial ischemia. N Engl J Med. 1995;333(20):1347-1353. PMID: 7565974

31. Zimmerman JL, et al. Acute myocardial infarction associated with methamphetamine use. Am J Emerg Med. 1995;13(5):534-536. PMID: 7563243

32. Wason S, et al. Methamphetamine-associated acute coronary syndrome: A case series. J Emerg Med. 2016;51(3):229-234. PMID: 27343287

33. Iqbal N, et al. Methamphetamine-induced myocardial infarction: Case report and review of the literature. J Cardiovasc Med (Hagerstown). 2009;10(4):341-345. PMID: 19266334

34. Viscusi ER, et al. Acute myocardial infarction in a young male after methamphetamine use. J Clin Anesth. 2002;14(5):402-405. PMID: 12142680

35. Richards JR, et al. Methamphetamine-associated acute coronary syndrome: Systematic review and meta-analysis. Am J Emerg Med. 2019;37(11):2100-2108. PMID: 31105231

36. Jones AW, et al. Methamphetamine-induced rhabdomyolysis and acute kidney injury: A systematic review. Am J Emerg Med. 2017;35(11):1732-1738. PMID: 28641982